The PN-to MES transition is recognized as the hallmark of malignant tumor progression, characterized by the upregulation of mesenchymal markers N-cadherin and Vimentin, and the downregulation of epithelial marker E-cadherin [6, 36, 37]. The gene discussed is CDH1; the disease is neoplasm.